Medications for Hairy Cell Leukemia (HCL)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hairy Cell Leukemia (HCL).
Found 2 Approved Drugs for Hairy Cell Leukemia (HCL)
Mavenclad
Generic Name
Cladribine
Mavenclad
Generic Name
Cladribine
Form: Injection, Tablet
Method of administration: Oral, Intravenous
FDA approval date: February 28, 2000
Classification: Purine Antimetabolite
FOR USE Cladribine Injection, USP is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms.
Nipent
Generic Name
Pentostatin
Nipent
Generic Name
Pentostatin
Form: Injection
Method of administration: Intravenous
FDA approval date: August 15, 2007
Classification: Nucleoside Metabolic Inhibitor
NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances